Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Weighted Average and Diluted) (2019 - 2025)

ImmunityBio (IBRX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.06 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 25.0% to -$0.06 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.38, a 38.71% increase, with the full-year FY2025 number at -$0.38, up 38.71% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.06 for Q4 2025 at ImmunityBio, up from -$0.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.06 in Q4 2025 to a low of -$0.37 in Q4 2023.
  • A 5-year average of -$0.2 and a median of -$0.22 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 37.04% in 2023, then skyrocketed 78.38% in 2024.
  • ImmunityBio's EPS (Weighted Average and Diluted) stood at -$0.23 in 2021, then fell by 17.39% to -$0.27 in 2022, then tumbled by 37.04% to -$0.37 in 2023, then surged by 78.38% to -$0.08 in 2024, then increased by 25.0% to -$0.06 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EPS (Weighted Average and Diluted) are -$0.06 (Q4 2025), -$0.07 (Q3 2025), and -$0.1 (Q2 2025).